STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Toxins and Toxics Review Article

Nanoformulation Strategies: Emerging Innovations in Drug Delivery Systems

  1. Tejas Naik Department of Pharmaceutics, Samarth Institute of Pharmacy, Belhe, Pune
  2. Sachin Datkhile Department of Pharmaceutics, Samarth Institute of Pharmacy, Belhe, Pune
  3. Sayali Wagh Department of Pharmaceutics, Samarth Institute of Pharmacy, Belhe, Pune
  4. Saniya Pathan Department of Pharmaceutics, Samarth Institute of Pharmacy, Belhe, Pune

Abstract

Nanotechnology is significantly advancing the pharmaceutical industry by introducing nanosystems that improve drug delivery, therapeutic efficacy, and patient outcomes. Various nanosystems-such as liposomes, dendrimers, polymeric nanoparticles, solid lipid nanoparticles, carbon nanotubes, and metallic nanoparticles-offer benefits like enhanced bioavailability, targeted delivery, improved stability, and reduced side effects. Innovative formulation strategies, including surface functionalization, particle size optimization, and use of biodegradable carriers, support controlled and sustained drug release. Additionally, production in non-aqueous media further enhances solubility and formulation efficiency. Despite these advancements, nano-formulations face challenges such as aggregation, manufacturing limitations, and regulatory compliance. Regulatory bodies like the FDA and EMA have established guidelines to ensure the safe development and application of nanomedicine. Looking ahead, nanotechnology play an important role in precision medicine, especially for treating cancer, neurological disorders, and infectious diseases. Moreover, its expanding applications in diagnostics and vaccine delivery underscore its importance in future of healthcare.

Keywords

References (111)

  1. Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using
  2. nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 2019;4(1).
  3. D.F. E, C.G. T. The pinpoint promise of nanoparticle-based drug delivery and
  4. molecular diagnosis. Biomol Eng. 2006;23(4):171–84. Available from:
  5. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&NEWS=N&
  6. AN=2006363798
  7. Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J
  8. Drug Target. 2007;15(3):163–83.
  9. Kaur IP, Singh H. Nanostructured drug delivery for better management of tuberculosis.
  10. J Control Release. 2014;184(1):36–50.
  11. Maruvada P, Wang W, Wagner PD, Srivastava S. Biomarkers in molecular medicine:
  12. cancer detection and diagnosis. Biotechniques. 2005;Suppl:9–15.
  13. Shukla T, Upmanyu N, Pandey SP, Sudheesh MS. Site-specific drug delivery,
  14. targeting, and gene therapy. Nanoarchitectonics Biomed. 2019;473–505.
  15. Mody V, Siwale R, Singh A, Mody H. Introduction to metallic nanoparticles. J Pharm
  16. Bioallied Sci. 2010;2(4):282.
  17. Alex S, Tiwari A. Functionalized gold nanoparticles: Synthesis, properties and
  18. applications-A review. J Nanosci Nanotechnol. 2015;15(3):1869–94.
  19. De Matteis V. Exposure to inorganic nanoparticles: Routes of entry, immune response,
  20. biodistribution and in vitro/In vivo toxicity evaluation. Toxics. 2017;5(4).
  21. Pochapski DJ, Carvalho Dos Santos C, Leite GW, Pulcinelli SH, Santilli CV. Zeta
  22. Potential and Colloidal Stability Predictions for Inorganic Nanoparticle Dispersions:
  23. Effects of Experimental Conditions and Electrokinetic Models on the Interpretation of
  24. Results. Langmuir. 2021;37(45):13379–89.
  25. Muro S. Challenges in design and characterization of ligand-targeted drug delivery
  26. systems. J Control Release. 2012;164(2):125–37.
  27. Wallace SJ, Li J, Nation RL, Boyd BJ. Drug release from nanomedicines: Selection of
  28. appropriate encapsulation and release methodology. Drug Deliv Transl Res.
  29. 2012;2(4):284–92.
  30. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on
  31. cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials.
  32. 2010;31(13):3657–66.
  33. Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of
  34. solid lipid nanoparticles using particle size and zeta potential. J Phys Sci.
  35. 2014;25(1):59–75.
  36. Chadha R, Bhandari S. Drug-excipient compatibility screening-Role of
  37. thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal. 2014;87:82–97.
  38. Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: Current
  39. understanding and recent trends. Drug Dev Ind Pharm. 2015;41(6):875–87.
  40. Xia D, Gan Y, Cui F. Application of Precipitation Methods for the Production of
  41. Water-insoluble Drug Nanocrystals: Production Techniques and Stability of
  42. Nanocrystals. Curr Pharm Des. 2014;20(3):408–35.
  43. Bhalani D V., Nutan B, Kumar A, Singh Chandel AK. Bioavailability Enhancement
  44. Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines.
  45. Jadhav SP, Singh SK, Chawra HS. Review on Nanosuspension as a Novel Method for
  46. Solubility and Bioavailability Enhancement of Poorly Soluble Drugs. Adv Pharmacol
  47. Pharm. 2023;11(2):117–30.
  48. Vinchhi P, Patel JK, Patel MM. High-pressure homogenization techniques for
  49. nanoparticles. Emerg Technol Nanoparticle Manuf. 2021;263–85.
  50. Kumar R, Dalvi S V., Siril PF. Nanoparticle-Based Drugs and Formulations: Current
  51. Status and Emerging Applications. ACS Appl Nano Mater. 2020;3(6):4944–61.
  52. Pardeshi S, More M, Patil P, Pardeshi C, Deshmukh P, Mujumdar A, et al. A
  53. meticulous overview on drying-based (spray-, freeze-, and spray-freeze) particle
  54. engineering approaches for pharmaceutical technologies. Dry Technol.
  55. 2021;39(11):1447–91.
  56. Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution
  57. and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics.
  58. Park H, Ha ES, Kim MS. Current status of supersaturable self-emulsifying drug
  59. delivery systems. Pharmaceutics. 2020;12(4).
  60. Trivedi NR, Rajan MG, Johnson JR, Shukla AJ. Pharmaceutical approaches to
  61. preparing pelletized dosage forms using the extrusion-spheronization process. Crit Rev
  62. Ther Drug Carrier Syst. 2007;24(1):1–40.
  63. Soni G, Kale K, Shetty S, Gupta MK, Yadav KS. Quality by design (QbD) approach in
  64. processing polymeric nanoparticles loading anticancer drugs by high pressure
  65. homogenizer. Heliyon. 2020;6(4).
  66. MÖSchwitzer J, Nadiem Bushrab F, MÜLler R. Manufacturing of Nanoparticles by
  67. Milling and Homogenization Techniques. 2006;
  68. Malamatari M, Somavarapu S, Taylor KMG, Buckton G. Solidification of
  69. nanosuspensions for the production of solid oral dosage forms and inhalable dry
  70. powders. Expert Opin Drug Deliv. 2016;13(3):435–50.
  71. Mauludin R. Nanosuspensions of Poorly Soluble Drugs for Oral Administration.
  72. 2008;(December):236.
  73. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. Electrospraying, spray
  74. drying and related techniques for production and formulation of drug nanoparticles.
  75. Expert Opin Drug Deliv. 2010;7(6):705–19.
  76. Di Pietro P, Strano G, Zuccarello L, Satriano C. Gold and Silver Nanoparticles for
  77. Applications in Theranostics. Curr Top Med Chem. 2016;16(27):3069–102.
  78. The Road from Nanomedicine to Precision Medicine. Road from Nanomedicine to
  79. Precis Med. 2019;
  80. Regulatory and Ethical Considerations. InHandbook of Biomaterials for Medical
  81. Applications.
  82. Kardani SL. Nanocarrier-based formulations: Regulatory Challenges, Ethical and
  83. Safety Considerations in Pharmaceuticals. Asian J Pharm. 2024;18(02).
  84. GABRIELLA B, KENNETH S. A. Introduction To Cosmetic Formulation and
  85. Technology. Wiley. 2015;725. Available from:
  86. http://www.ncbi.nlm.nih.gov/pubmed/15003161%5Cnhttp://cid.oxfordjournals.org/loo
  87. kup/doi/10.1093/cid/cir991%5Cnhttp://www.scielo.cl/pdf/udecada/v15n26/art06.pdf%
  88. 5Cnhttp://www.scopus.com/inward/record.url?eid=2-s2.0-
  89. 84861150233&partnerID=tZOtx3y1
  90. Nanda S, Nanda A, Lohan S, Kaur R, Singh B. Nanocosmetics: Performance
  91. enhancement and safety assurance. Nanobiomaterials Galen Formul Cosmet Appl
  92. Nanobiomaterials. 2016;47–67.
  93. Athulya R, Nandini J, Bhoi TK, Sundararaj R. Recent advances of nanotechnology in
  94. wood protection: a comprehensive review. Wood Mater Sci Eng. 2024;19(2):279–90.
  95. Mandracchia D, Tripodo G. Micro and Nano-drug Delivery Systems. Silk-based Drug
  96. Deliv Syst. 2020;1–24.
  97. Tian H, Chen J, Chen X. Nanoparticles for gene delivery. Small. 2013;9(12):2034–44.
  98. Wahane A, Waghmode A, Kapphahn A, Dhuri K, Gupta A, Bahal R. Role of lipid-
  99. based and polymer-based non-viral vectors in nucleic acid delivery for next-generation
  100. gene therapy. Molecules. 2020;25(12).
  101. Huang JG, Leshuk T, Gu FX. Emerging nanomaterials for targeting subcellular
  102. organelles. Nano Today. 2011;6(5):478–92.
  103. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug
  104. delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351–70.
  105. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted
  106. imaging and therapy. Adv Drug Deliv Rev. 2008;60(11):1241–51.
  107. Zhou X, Pu H, Sun DW. DNA functionalized metal and metal oxide nanoparticles:
  108. principles and recent advances in food safety detection. Crit Rev Food Sci Nutr.
  109. 2021;61(14):2277–96.
  110. Nanoparticles for Brain Drug Delivery. Nanoparticles Brain Drug Deliv. 2021;
  111. Crossing the blood–brain barrier: recent advances in drug delivery to the brain.